Skip to main content
Top
Published in: Drug Safety 12/2017

Open Access 01-12-2017 | Original Research Article

Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

Authors: Rachel B. Weinstein, Patrick Ryan, Jesse A. Berlin, Amy Matcho, Martijn Schuemie, Joel Swerdel, Kayur Patel, Daniel Fife

Published in: Drug Safety | Issue 12/2017

Login to get access

Abstract

Introduction

Over-the-counter analgesics such as paracetamol and ibuprofen are among the most widely used, and having a good understanding of their safety profile is important to public health. Prior observational studies estimating the risks associated with paracetamol use acknowledge the inherent limitations of these studies. One threat to the validity of observational studies is channeling bias, i.e. the notion that patients are systematically exposed to one drug or the other, based on current and past comorbidities, in a manner that affects estimated relative risk.

Objectives

The aim of this study was to examine whether evidence of channeling bias exists in observational studies that compare paracetamol with ibuprofen, and, if so, the extent to which confounding adjustment can mitigate this bias.

Study Design and Setting

In a cohort of 140,770 patients, we examined whether those who received any paracetamol (including concomitant users) were more likely to have prior diagnoses of gastrointestinal (GI) bleeding, myocardial infarction (MI), stroke, or renal disease than those who received ibuprofen alone. We compared propensity score distributions between drugs, and examined the degree to which channeling bias could be controlled using a combination of negative control disease outcome models and large-scale propensity score matching. Analyses were conducted using the Clinical Practice Research Datalink.

Results

The proportions of prior MI, GI bleeding, renal disease, and stroke were significantly higher in those prescribed any paracetamol versus ibuprofen alone, after adjusting for sex and age. We were not able to adequately remove selection bias using a selected set of covariates for propensity score adjustment; however, when we fit the propensity score model using a substantially larger number of covariates, evidence of residual bias was attenuated.

Conclusions

Although using selected covariates for propensity score adjustment may not sufficiently reduce bias, large-scale propensity score matching offers a novel approach to consider to mitigate the effects of channeling bias.
Appendix
Available only for authorised users
Footnotes
1
 Examples of conditions include essential hypertension, dyspnea and osteoarthritis.
 
2
 Examples of drugs include analgesics, antithrombotic agents, and codeine.
 
3
 Examples of a procedure, measurement and observation include heart valve replacement, creatinine measurement and CHADS2 stroke risk score, respectively.
 
Literature
1.
go back to reference Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42:234–44.PubMedCrossRef Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42:234–44.PubMedCrossRef
2.
go back to reference Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204–8.PubMedCrossRef Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204–8.PubMedCrossRef
3.
go back to reference Dedier J, Stampfer M, Hankinson S, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604–8.PubMedCrossRef Dedier J, Stampfer M, Hankinson S, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604–8.PubMedCrossRef
4.
go back to reference Chan AT, Manson JE, Albert CM, et al. Nonsteroidal anti-inflammatory drugs, paracetamol, and the risk of cardiovascular events. Circulation. 2006;113:1578–87.PubMedCrossRef Chan AT, Manson JE, Albert CM, et al. Nonsteroidal anti-inflammatory drugs, paracetamol, and the risk of cardiovascular events. Circulation. 2006;113:1578–87.PubMedCrossRef
5.
go back to reference Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009;24:1908–18.PubMedCrossRef Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009;24:1908–18.PubMedCrossRef
6.
go back to reference Lipworth L, Friis S, Mellemkjaer L, et al. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol. 2003;56:796–801.PubMedCrossRef Lipworth L, Friis S, Mellemkjaer L, et al. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol. 2003;56:796–801.PubMedCrossRef
7.
go back to reference de Vries F, Setakis E, van Staa TP, et al. Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol. 2010;70:429–38.PubMedPubMedCentralCrossRef de Vries F, Setakis E, van Staa TP, et al. Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol. 2010;70:429–38.PubMedPubMedCentralCrossRef
8.
go back to reference Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, Doherty M, Zhang W, Birrell F, Porcheret M, Dziedzic K, Bernstein I, Wise E, Conaghan PG. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552–9.PubMedCrossRef Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, Doherty M, Zhang W, Birrell F, Porcheret M, Dziedzic K, Bernstein I, Wise E, Conaghan PG. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552–9.PubMedCrossRef
9.
go back to reference Herret E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.CrossRef Herret E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.CrossRef
10.
go back to reference Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a Clinical Practice Research Datalink conversion to the OMOP common data model. Drug Saf. 2014;37:945–59.PubMedPubMedCentralCrossRef Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a Clinical Practice Research Datalink conversion to the OMOP common data model. Drug Saf. 2014;37:945–59.PubMedPubMedCentralCrossRef
11.
go back to reference Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc B. 1996;58(1):267–88. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc B. 1996;58(1):267–88.
12.
go back to reference Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res. 2013;2013(3):11–20. Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res. 2013;2013(3):11–20.
13.
go back to reference Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68:627–36.PubMedCrossRef Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68:627–36.PubMedCrossRef
15.
go back to reference Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. Bethesda: American Society of Health-System Pharmacists; 2010. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. Bethesda: American Society of Health-System Pharmacists; 2010.
16.
go back to reference Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209–18.PubMedCrossRef Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209–18.PubMedCrossRef
Metadata
Title
Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
Authors
Rachel B. Weinstein
Patrick Ryan
Jesse A. Berlin
Amy Matcho
Martijn Schuemie
Joel Swerdel
Kayur Patel
Daniel Fife
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 12/2017
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-017-0581-7

Other articles of this Issue 12/2017

Drug Safety 12/2017 Go to the issue